M
M. Kerry O'Banion
Researcher at University of Rochester
Publications - 113
Citations - 7847
M. Kerry O'Banion is an academic researcher from University of Rochester. The author has contributed to research in topics: Neuroinflammation & Microglia. The author has an hindex of 41, co-authored 100 publications receiving 7022 citations. Previous affiliations of M. Kerry O'Banion include State University of New York System & University of Münster.
Papers
More filters
Journal ArticleDOI
Inflammatory processes in Alzheimer's disease.
TL;DR: While inflammation has been thought to arise secondary to degeneration, recent experiments demonstrated that inflammatory mediators may stimulate APP processing by upregulation of beta secretase 1 and therefore are able to establish a vicious cycle.
Journal ArticleDOI
ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration
Zhihui Zhong,Rashid Deane,Zarina S. Ali,Margaret Parisi,Yuriy Shapovalov,M. Kerry O'Banion,Konstantin Stojanovic,Abhay P. Sagare,Séverine Boillée,Don W. Cleveland,Berislav V. Zlokovic +10 more
TL;DR: It is reported here that amyotrophic lateral sclerosis–linked superoxide dismutase 1 (SOD1) mutants with different biochemical characteristics disrupted the blood–spinal cord barrier in mice by reducing the levels of the tight junction proteins ZO-1, occludin and claudin-5 between endothelial cells.
Journal ArticleDOI
The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective.
TL;DR: Potentially adaptive functions of IL-1 elevation in AD warrant further mechanistic studies, and provide evidence that enhancement of these effects may help to alleviate the pathologic burden of disease.
Journal ArticleDOI
Sustained hippocampal IL-1β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology
Solomon S. Shaftel,Stephanos Kyrkanides,John A. Olschowka,Jen-nie H. Miller,Renee E. Johnson,M. Kerry O'Banion +5 more
TL;DR: A transgenic mouse model of sustained IL-1 beta overexpression that was capable of driving robust neuroinflammation lasting months after transgene activation is described, characterized by astrocytic and microglial activation in addition to induction of proinflammatory cytokines.
Journal ArticleDOI
Neuroinflammatory processes in Alzheimer's disease.
TL;DR: Non-steroidal anti-inflammatory drugs have been shown to reduce the risk and delay the onset to develop AD and a number of possible mechanisms including cyclooxygenase 2 or γ-secretase inhibition and activation of the peroxisome proliferator activated receptor γ may alone or in concert account for the epidemiologically observed protection.